



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM


DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

1646
RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

August 15, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
August 15, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" by Paul B. McCray, Jr. et al.*
Our Reference: IOWA:031US
Client Reference: UIRF:M0-49


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A1, B5-B6).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted
25197861.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:
Paul B. McCray, Jr. *et al.*

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
August 15, 2002	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.


Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 15, 2002



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

IOWA:031US

Serial No.

09/872,852

Applicant

Paul B. McCray, Jr. *et al.*

Filing Date:

June 1, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>W</i>	A1	6,399,370 B1	6/4/02	Wilson <i>et al.</i>	435	325	1/12/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B5	DE 10033505.5	7/11/00	Germany			No
<i>W</i>	B6	WO 02/04487	1/17/02	PCT			Yes

Abstract only

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25197847.1

EXAMINER:

Hope Robinson

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 24, 2002

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 24, 2002	Steven L. Highlander
Date	

Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" by Paul B. McCray, Jr. et al.
Our Reference: IOWA:031US
Client Reference: UIRF:M0-49

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (B1-B4).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted
25189868.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Paul B. McCray, Jr. *et al*

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE



Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 24, 2002	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 24, 2002

Form PTO-1449 (modified)

Atty. Docket No.

IOWA:031US

Serial No.

09/872,852

List of Patents and Publications for Applicant's

Applicant

Paul B. McCray, Jr. *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 1, 2001

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>MB</i>	B1	WO 00/46245	8/10/00	PCT	—	—	
	B2	WO 02/04487	1/17/02	PCT	—	—	
	B3	WO 02/09738	2/7/02	PCT	—	—	
<i>✓</i>	B4	WO 99/13080	3/18/99	PCT	—	—	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

RECEIVED
AUG 01 2002
TECH CENTER 1600/2900

25189853.1

EXAMINER:

Dope Robinson

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



1646

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/471-1201
FACSIMILE: 512/536-3184
STEVEN L. HIGHLANDER
PARTNER
INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM
DIRECT DIAL: 512/536-3184

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

PHS

RECEIVED

APR 11 2002

April 4, 2002

TECH CENTER 1600/2900 FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R. § 8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 4, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: *SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" – Paul B. McCray, Jr., et al. (Client Reference: URIF:M0-49)*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C15).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl: as noted



THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED

In re Application of:

Paul B. McCray, Jr., *et al.*

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH

APR 11 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 4, 2002	
Date	Steven J. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 4, 2002

Form PTO-1449 (modified)


Atty. Docket No.
IOWA:031US/SLHSerial No.
09/872,852

List of Patents and Publications for Applicant's

Applicant
Paul B. McCray, Jr., *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
June 1, 2001Group:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

TECH CENTER 1600/2940

APR 11 2002

RECEIVED

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>HW</i>	C15	Co-pending U.S. Patent Application Serial Number 09/642,744 by Brian F. Tack <i>et al.</i> , filed August 18, 2000.

25151217.1

EXAMINER:

Hope Robinson

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

TELEPHONE: 512/474-5252
FACSIMILE: 512/536-3188
STEVEN L. HIGHLANDER
PARTNER
INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM
DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

RECEIVED


DEC 04 2001

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

October 29, 2001

TECH CENTER 1600/2900

FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 29, 2001	
Date	
	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" – Paul B. McCray, Jr., et al. (Client Reference: URIF:MO-49)


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb

Encl: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:

Paul B. McCray, Jr., *et al.*

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH

#7 12/20/01
Bray

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
October 29, 2001	
Date	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 29, 2001

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

IOWA:031US/SLH

09/872,852

List of Patents and Publications for Applicant's

Applicant

Paul B. McCray, Jr., *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

June 1, 2001

1646

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<input checked="" type="checkbox"/>	C1	Gallo, <i>et al.</i> , "Antimicrobial peptides: an emerging concept in cutaneous biology," <i>J. Invest Dermatol</i> , 111(5):739-743, 1998.
<input type="checkbox"/>	C2	Ganz and Lehrer, "Antimicrobial peptides of vertebrates," <i>Current Opinions Immun</i> , 10:41-44, 1998.
<input type="checkbox"/>	C3	Hamil <i>et al.</i> , "HE2 β and HE2 γ , new members of an epididymis-specific family of androgen-regulated proteins in the human," <i>Endocrinology</i> , 141(3): 1245-1253, 2000.
<input type="checkbox"/>	C4	Harder <i>et al.</i> , "Short communication—Mapping of the gene encoding human β -Defensin-2 (DEFB2) to chromosome region 8p22-p23.1," <i>Genomics</i> , 46:472-475, 1997.
<input type="checkbox"/>	C5	Jia <i>et al.</i> , "Discovery of new human β -defensins using a genomics-based approach," <i>Gene</i> , 263:211-218, 2001.
<input type="checkbox"/>	C6	Kirchhoff <i>et al.</i> , "CD52 mRNA is modulated by androgens and temperature in epididymal cell cultures," <i>Mol. Reprod. Dev.</i> , 56:26-33, 2000.
<input type="checkbox"/>	C7	Krull <i>et al.</i> , "Region-specific variation of gene expression in the human epididymis as revealed by in situ hybridization with tissue-specific cDNAs," <i>Mol. Reprod. Dev.</i> , 34:16-24, 1993.
<input checked="" type="checkbox"/>	C8	Liu <i>et al.</i> , "Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NF κ B, c-fos/c-jun, and p53 proteins," <i>Mol. Carcinog.</i> , 22:235-246, 1998.

25066728.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

IOWA:031US/SLH

Serial No.

09/872,852

List of Patents and Publications for Applicant's

Applicant

Paul B. McCray, Jr., *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

June 1, 2001

Group:

1646

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>MR</i>	C9	Mathews <i>et al.</i> , "Production of β -defensin antimicrobial peptides by the oral mucosa and salivary glands," <i>Infect Immun.</i> , 67(6):2740-2745, 1999.
	C10	Nilsson <i>et al.</i> , "Patient education for adults with chronic eczema," <i>Dermatol Nurs</i> , 11(2):117-122, 1999.
	C11	Oren and Shai, "Mode of action of linear amphipathic α -helical antimicrobial peptides," <i>Biopolymers</i> , 47:451-463, 1998.
	C12	Osterhoff <i>et al.</i> , "Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis," <i>Biol Reprod</i> , 50:516-525, 1994.
	C13	Russell <i>et al.</i> , "Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha," <i>Infect Immun.</i> , 64(5):1565-1568, 1996.
	C14	Singh <i>et al.</i> , "Production of β -defensins by human airway epithelia," <i>Proc. Natl. Acad. Sci USA</i> , 95:14961-14966, 1998.

25066728.1

EXAMINER:

Hope Robinson

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.